Company Description
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Feb 3, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 829 |
| CEO | Frank Lee |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 900 Brisbane, California 94005 United States | |
| Phone | 650 242 8052 |
| Website | pacira.com |
Stock Details
| Ticker Symbol | PCRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001396814 |
| CUSIP Number | 695127100 |
| ISIN Number | US6951271005 |
| Employer ID | 51-0619477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frank D. Lee | Chief Executive Officer and Director |
| Shawn M. Cross | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 13, 2026 | DFAN14A | Filing |
| May 12, 2026 | DEFC14A | Filing |
| May 12, 2026 | DFAN14A | Filing |
| May 12, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 8, 2026 | PRRN14A | Filing |
| May 5, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 1, 2026 | SCHEDULE 13G | Filing |
| May 1, 2026 | SCHEDULE 13G | Filing |
| Apr 30, 2026 | 10-Q | Quarterly Report |